Part 2: Reducing Risks with Opioid Use
Reducing Risks with Opioid Use is part 2 of the 3-part curriculum, Strategies for Effective Pain Management in Clinical Practice, which examines the full spectrum of pain management options available to clinicians, including the safe and effective use of opioids.
In Part 2, you will learn about different opioids available for pain management and best practices for reducing risk associated with opioid use. You will also learn how to recognize signs of opioid use disorder and distinguish it from tolerance and physical dependence, and how to recognize and treat opioid overdose in your patients.
Information on the entire curriculum, including learning objectives, is located here.
This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://www.opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FDA).
- Differentiate among tolerance, physical dependence, and addiction
- Recognize best practices to reduce the risks associated with prescription of opioid analgesics, as well as safe storage and disposal
- Distinguish signs of opioid use disorder as well as signs of overdose and its treatment
Charles E. Argoff, MD, FABPM:
Professor of Neurology
Albany Medical College
Director, Comprehensive Pain Center
Albany Medical Center
Oscar A. de Leon-Casasola, MD:
Professor of Anesthesiology and Medicine
The Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo
Chief, Pain Medicine and Professor of Oncology
Roswell Park Cancer Institute
Katherine E. Galluzzi, DO, CMD, FACOFP:
Professor and Chair
Department of Geriatrics
Philadelphia College of Osteopathic Medicine
The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.
Charles E. Argoff, MD, FABPM: Speaker’s bureau: AbbVie, Amgen, Averitas Pharma, Biohaven, Grunenthal, Impel, Kowa Pharmaceuticals America, Lilly, Lundbeck, Neumentum, Nevro, Redhill Biopharma, and Teva Pharmaceuticals. Advisory Board: AbbVie, Amgen, Averitas Pharma, BioDelivery Sciences International, Clexio Biosciences, EnZen Therapeutics, Kowa, Lundbeck, Nevro, Regeneron, SK Life Sciences, Tremeau Pharmaceuticals, Teva, Tris, Vertex and Xgene Pharma. Consulting: EnZen Therapeutics, Neumentum, Opioid PMR Consortium, PainScripts, and Xgene Pharmaceutical. Researcher: AbbVie, Allergan, Amgen, Lilly, Lundbeck, and Teva. Royalties or patent beneficiaries: Elsevier. Stock Holder: Pfizer and Trevena. Other services provided: Collegium.
Oscar A. de Leon-Casasola, MD: Advisory board: Heron Therapeutics and Tremeau Pharmaceuticals. Consultant: Kowa Pharmaceuticals.
Katherine E. Galluzzi, DO, CMD, FACOFP: No relevant financial relationships to disclose.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
AMA PRA Category 1 Credits™
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and Miller Medical Communications. Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians.
Pri-Med Institute designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of Pri-Med Institute and Miller Medical Communications. Pri-Med Institute is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider Number 040308.
This activity is approved for 1.07 contact hours of continuing education, which includes 0.71 hours of pharmacology.
MOC Credit Information
Successful completion of this CME activity (“Strategies for Effective Pain Management in Clinical Practice”), which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge & Patient Safety MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
State Licensure Requirements
This activity satisfies topic-specific CME/CE requirements (pain management, controlled substances, etc.) of many state licensing boards. Please check with your state’s licensing boards for specific requirements, and print this page as appropriate for documentation.
Texas: This activity is approved for Pain Management and Prescription of Opioids requirements from the Texas Medical Board/Board of Nursing, which may also satisfy the medical ethics and/or professional responsibility.
Iowa: This activity is designed to satisfy requirements of ARNPs, for CE regarding the US Centers for Disease Control and Prevention Guideline for prescribing opioids for chronic pain. Please print this page as documentation, for submission with your CE certificate.
Instructions for Obtaining Credit
Once you have completed the activity, please click the "next" button to advance to the post-activity assessment. To complete this activity and claim credit, you must answer 2 out of the 3 questions correctly. If you are not successful after your first attempt, you will be given an opportunity to reflect upon the answer rationales and have the opportunity to review the educational content before proceeding. Once you have selected your answers, click the "submit" button to complete the evaluation questions and proceed to the claim credit screen. For PAs, the NCCPA accepts for Category 1 CME credit activities designated for AMA PRA Category 1 Credit.
- 1.07 AANP Contact Hours
- 0.71 AANP Pharmacology Contact Hours
- 1.00 MOC
- 1.00 AMA PRA Category 1 Credit™
This course is offered through Pri-Med.
To take this course you will be redirected to Pri-Med's website. You must login or create an account with Pri-Med in order to complete this activity.
Mocingbird works to provide curated, high quality content to our users. Have a suggestion? Want to partner with us? Get in touch!